Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Int. braz. j. urol ; 39(1): 10-21, January-February/2013. tab, graf
Article Dans Anglais | LILACS | ID: lil-670376

Résumé

Purpose: To assess the changing presentation and treatment of nonseminomatous testicular germ cell tumors (NSGCT) and to investigate predictive factors for the status of metastasis at diagnosis and on relapse and death. Materials and Methods: Retrospective record review of 147 patients that underwent inguinal orchiectomy from 1987-2007. Follow-up data was available for 102 patients (median follow-up: 80 months (0-243); 96 patients alive). Results: Mean patients age increased (p = 0.015) and more patients were diagnosed in clinical stage I (CSI) (p = 0.040). The fraction of yolk sac (YS) elements inclined (p = 0.030) and pT2 tumors increased (p < 0.001). Retroperitoneal lymph node dissection (RPLND) declined whereas more patients were treated with chemotherapy (p < 0.001; p = 0.004). There was an increase in relapse free (RFS) and cancer specific survival (CSS) due to an improvement in patients with disseminated disease (p = 0.014; p < 0.001). The presence of YS and teratoma elements showed a reduction in the odds ratio (OR) for metastasis at diagnosis (p = 0.002, OR: 0.262; p = 0.009, OR: 0.428) whereas higher pT-stage was associated to their presence (p = 0.039). Patients with disseminated disease (CS > I) showed a declined CSS compared to CSI patients (p = 0.055). The presence of YS elements was associated to an improved RFS (p = 0.038). Conclusions: In our single institution study the face of NSGCT markedly changed over 20 years even after the introduction of Cisplatin-based chemotherapy. These changes were accompanied by an improvement in RFS and CSS. When dealing with NSGCT patients such observations now and in the future should be taken into account. .


Sujets)
Humains , Mâle , Antinéoplasiques/usage thérapeutique , Cisplatine/usage thérapeutique , Tumeurs embryonnaires et germinales/traitement médicamenteux , Tumeurs du testicule/traitement médicamenteux , Survie sans rechute , Stadification tumorale , Tumeurs embryonnaires et germinales/mortalité , Tumeurs embryonnaires et germinales/secondaire , Orchidectomie , Valeur prédictive des tests , Études rétrospectives , Facteurs de risque , Facteurs temps , Tumeurs du testicule/mortalité , Tumeurs du testicule/secondaire
SÉLECTION CITATIONS
Détails de la recherche